CD110 Polyclonal Antibody

• Background:

  MPL proto-oncogene, thrombopoietin receptor (MPL) Homo sapiens In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important

• Product Name Alternative:

  MPL; TPOR; Thrombopoietin receptor; TPO-R; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; CD antigen CD110

• Gene ID:

  4352

• Swiss Prot:

  P40238

• Cross Reactivity:

  Human; Rat; Mouse

• Clonality:

  Polyclonal

• Source:

  Rabbit

• Applications:

  WB; ELISA

• Dilution:

  Western Blot: 1/500 - 1/2000. ELISA: 1/10000. Not yet tested in other applications.

• Buffer:

  Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Molecular Weight:

  71

• Storage Conditions:

  -20°C/1 year

• Protein Weight:

  71